Signpath Pharma 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 28, 2014	Jun. 28, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'SIGNPATH PHARMA, INC.	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Entity Central Index Key	'0001455694	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	12,877,500	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Public Float	'	'	$0
Entity Incorporation, State Country Name	'Delaware	'	'
Entity Incorporation, Date of Incorporation	15-May-06	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Cash	$1,241,397	$31,922
Total Current Assets	1,241,397	31,922
EQUIPMENT, net	'	144
TOTAL ASSETS	1,241,397	32,066
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	421,632	894,475
Derivative liability	'	5,687,262
Total Current Liabilities	421,632	6,581,737
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock; $0.10 par value, 5,000,000 shares authorized 8,532 and 4,286 shares issued and outstanding, respectively	879	541
Common stock; $0.001 par value, 45,000,000 shares authorized; 12,877,500 and 12,837,500 shares issued and outstanding, respectively	12,879	12,839
Accrued dividends	1,353,961	861,872
Additional paid-in capital	10,120,454	1,286,613
Deficit accumulated during the development stage	-10,668,408	-8,711,536
Total Stockholders' Equity (Deficit)	819,765	-6,549,671
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$1,241,397	$32,066

BALANCE_SHEET_PARENTHETICAL

BALANCE SHEET PARENTHETICAL (USD $)	Dec. 31, 2013	Dec. 31, 2012
BALANCE SHEET PARENTHETICAL	'	'
Convertible preferred stock par value	$0.10	$0.10
Convertible preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	8,532	4,286
Preferred stock shares outstanding	8,532	4,286
Common stock par value	$0.00	$0.00
Common stock shares authorized	45,000,000	45,000,000
Common stock shares issued	12,877,500	12,837,500
Common stock shares outstanding	12,877,500	12,837,500

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended		92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Statements of Operations	'	'	'
REVENUES	'	'	'
OPERATING EXPENSES	'	'	'
General and administrative	53,957	45,596	1,303,596
Professional fees	808,865	121,586	1,784,218
Financing expense	'	'	1,063,401
Research and development	841,502	939,296	4,297,433
Salaries and wages	249,407	205,927	1,249,329
Total Operating Expenses	1,953,731	1,312,405	9,697,977
OPERATING LOSS	-1,953,731	-1,312,405	-9,697,977
OTHER INCOME (EXPENSE)	'	'	'
Gain (loss) on derivative liability	-3,926	-8,154	-998,403
Gain on shares issued for services	'	9,625	9,625
Grant income	'	'	81,556
Interest income	785	'	785
Interest expense	'	'	-63,995
Total Other Income (Expense)	-3,141	1,471	-970,432
NET LOSS BEFORE INCOME TAXES	-1,956,872	-1,310,934	-10,668,408
Provision for income taxes	'	'	'
NET LOSS	-1,956,872	-1,310,934	-10,668,408
DEEMED DIVIDEND ON WARRANTS	-2,445,621	'	-2,445,621
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	($4,402,493)	($1,310,934)	($13,114,029)
BASIC AND DILUTED LOSS PER SHARE	($0.34)	($0.10)	'
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	12,877,500	12,833,258	'

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Preferred Stock	Common Stock	Accrued Dividends	Additional Paid in Capital	Deficit Accumulated During the Development Stage	Total
Balance at May. 15, 2006	'	'	'	'	'	'
Common stock issued to founders for cash at $0.001 per share	'	$10,000	'	'	'	$10,000
Common stock issued to founders for cash at $0.001 per share - shares	'	10,000,000	'	'	'	'
Balance at Dec. 31, 2006	'	10,000	'	'	'	10,000
Balance - shares at Dec. 31, 2006	'	10,000,000	'	'	'	'
Common stock issued for bridge debt at $0.85 per share	'	258	'	218,617	'	218,875
Common stock issued for bridge debt at $0.85 per share - shares	'	257,500	'	'	'	'
Net loss	'	'	'	'	-526,833	-526,833
Balance at Dec. 31, 2007	'	10,258	'	218,617	-526,833	-297,958
Balance - shares at Dec. 31, 2007	'	10,257,500	'	'	'	'
Preferred stock issued for bridge debt at $1,000 per share	89	'	'	889,786	'	889,875
Preferred stock issued for bridge debt at $1,000 per share - shares	890	'	'	'	'	'
Preferred stock issued for cash at $1,000 per share	56	'	'	561,944	'	562,000
Preferred stock issued for cash at $1,000 per share - shares	562	'	'	'	'	'
Common stock issued for bridge debt at $0.85 per share	'	1,083	'	919,043	'	920,126
Common stock issued for bridge debt at $0.85 per share - shares	'	1,082,500	'	'	'	'
Stock offering costs	'	'	'	-270,948	'	-270,948
Preferred dividend accrued	'	'	9,308	-9,308	'	'
Net loss	'	'	'	'	-1,695,766	-1,695,766
Balance at Dec. 31, 2008	145	11,341	9,308	2,309,134	-2,222,599	107,329
Balance - shares at Dec. 31, 2008	1,452	11,340,000	'	'	'	'
Preferred stock issued for cash at $1,000 per share	81	'	'	-178,632	'	-178,551
Preferred stock issued for cash at $1,000 per share - shares	810	'	'	'	'	'
Cumulative effect of adoption of ASC 815	'	'	'	-1,632,825	-43,808	-1,676,633
Stock offering costs	'	'	'	-166,154	'	-166,154
Preferred dividend accrued	'	'	124,576	-124,576	'	'
Net loss	'	'	'	'	-730,743	-730,743
Balance at Dec. 31, 2009	226	11,341	133,884	206,947	-2,997,150	-2,644,752
Balance - shares at Dec. 31, 2009	2,262	11,340,000	'	'	'	'
Preferred stock issued for cash at $1,000 per share	58	'	'	574,942	'	575,000
Preferred stock issued for cash at $1,000 per share - shares	575	'	'	'	'	'
Stock offering costs	'	'	'	-121,709	'	-121,709
Common stock issued for services	'	850	'	721,650	'	722,500
Common stock issued for services - shares	'	850,000	'	'	'	'
Amortization of options issued for services	'	'	'	39,210	'	39,210
Adjustment for derivative liability	'	'	'	-852,346	'	-852,346
Preferred dividend accrued	'	'	157,609	-157,609	'	'
Net loss	'	'	'	'	-2,119,059	-2,119,059
Balance at Dec. 31, 2010	284	12,191	291,493	411,085	-5,116,209	-4,401,156
Balance - shares at Dec. 31, 2010	2,837	12,190,000	'	'	'	'
Preferred stock issued for cash at $1,000 per share	145	'	'	1,448,355	'	1,448,500
Preferred stock issued for cash at $1,000 per share - shares	1,449	'	'	'	'	'
Stock offering costs	'	'	'	-267,966	'	-267,966
Common stock issued for services	'	640	'	543,360	'	544,000
Common stock issued for services - shares	'	640,000	'	'	'	'
Amortization of options issued for services	'	'	'	23,368	'	23,368
Adjustment for derivative liability	'	'	'	-917,263	'	-917,263
Preferred dividend accrued	'	'	219,082	-219,082	'	'
Net loss	'	'	'	'	-2,284,393	-2,284,393
Balance at Dec. 31, 2011	429	12,831	510,575	1,021,857	-7,400,602	-5,854,910
Balance - shares at Dec. 31, 2011	4,286	12,830,000	'	'	'	'
Preferred stock issued for cash	112	'	'	1,115,889	'	1,116,001
Preferred stock issued for cash - shares	1,116	'	'	'	'	'
Stock offering costs	'	'	'	-221,175	'	-221,175
Common stock issued for services	'	8	'	6,367	'	6,375
Common stock issued for services - shares	'	7,500	'	'	'	'
Amortization of options issued for services	'	'	'	16,772	'	16,772
Adjustment for derivative liability	'	'	'	-301,800	'	-301,800
Preferred dividend accrued	'	'	351,297	-351,297	'	'
Net loss	'	'	'	'	-1,310,934	-1,310,934
Balance at Dec. 31, 2012	541	12,839	861,872	1,286,613	-8,711,536	-6,549,671
Balance - shares at Dec. 31, 2012	5,402	12,837,500	'	'	'	'
Preferred stock issued for cash	338	'	'	3,379,662	'	3,380,000
Preferred stock issued for cash - shares	3,380	'	'	'	'	'
Stock offering costs	'	'	'	-550,326	'	-550,326
Common stock issued for services	'	40	'	33,960	'	34,000
Common stock issued for services - shares	'	40,000	'	'	'	'
Amortization of options issued for services	'	'	'	667,449	'	667,449
Executive forfeited salary	'	'	'	104,000	'	104,000
Adjustment for derivative liability	'	'	'	5,691,185	'	5,691,185
Preferred dividend accrued	'	'	492,089	-492,089	'	'
Net loss	'	'	'	'	-1,956,872	-1,956,872
Balance at Dec. 31, 2013	$879	$12,879	$1,353,961	$10,120,454	($10,668,408)	$819,765
Balance - shares at Dec. 31, 2013	8,782	12,877,500	'	'	'	'

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	8 Months Ended	12 Months Ended
	Dec. 31, 2006	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)	'	'	'	'	'	'
Common stock issued to founders for cash price per share	$0.00	'	'	'	'	'
Common stock issued for bridge debt price per share	'	'	'	'	$0.85	$0.85
Preferred Stock Issued for Bridge Debt per share price	'	'	'	'	$1,000	'
Preferred Stock Issued for cash per share price	'	$1,000	$1,000	$1,000	$1,000	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended		92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
OPERATING ACTIVITIES	'	'	'
Net loss	($1,956,872)	($1,310,934)	($10,668,408)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Common stock issued for services	34,000	6,375	1,306,875
Options issued for services	667,449	16,772	746,799
Common stock issued with bridge financing	'	'	1,139,001
Depreciation expense	144	1,265	5,390
Change in derivative liability, net of bifurcation	3,926	8,154	998,403
Changes in operating assets and liabilities	'	'	'
Change in accounts payable and accrued expenses	-368,846	395,040	525,629
Net Cash Used in Operating Activities	-1,620,199	-883,328	-5,946,311
INVESTING ACTIVITIES	'	'	'
Purchase of equipment	'	'	-5,390
Net Cash Used in Investing Activities	'	'	-5,390
FINANCING ACTIVITIES	'	'	'
Preferred stock issued for cash	3,380,000	1,116,001	7,891,501
Stock offering costs paid	-550,326	-221,175	-1,598,278
Common stock issued for cash	'	'	10,000
Proceeds from related party notes payable	30,000	'	30,000
Proceeds from notes payable	'	55,075	944,950
Repayment of related party notes payable	-30,000	'	-30,000
Repayment of notes payable	'	-55,075	-55,075
Net Cash Provided by Financing Activities	2,829,674	894,826	7,193,098
NET INCREASE IN CASH	1,209,475	11,498	1,241,397
CASH AT BEGINNING OF PERIOD	31,922	20,424	'
CASH AT END OF PERIOD	1,241,397	31,922	1,241,397
CASH PAID FOR:	'	'	'
Interest	'	'	'
Income taxes	'	'	'
NON CASH FINANCING ACTIVITIES:	'	'	'
Preferred stock issued for bridge financing	'	'	889,875
Derivative liability non cash financing activity	'	301,800	4,692,786
Executive forfeited salary	104,000	'	104,000
Settlement of derivative liability	5,691,185	'	5,691,185
Preferred dividend accrual	$492,089	$351,298	$1,353,961

Note_1_Nature_of_Operations

Note 1 - Nature of Operations	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 1 - Nature of Operations	'
	NOTE 1 – NATURE OF OPERATIONS
	SignPath Pharma, Inc., (the “Company”) was incorporated under the laws of the State of Delaware on May 15, 2006.  The Company was organized to develop proprietary formulations of curcumin (diferuloylmethane), a naturally occurring compound found in the root of the Curcuma longa (turmeric) plant, for applications in malignant diseases.  The Company’s product candidates are currently in the pre-clinical testing phase.

Note_2_Going_Concern

Note 2 - Going Concern	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 2 - Going Concern	'
	NOTE 2 - GOING CONCERN
	The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. During the year ended December 31, 2013, the Company recognized sales revenue of~ $-0- and incurred a net loss of $1,956,872.  As of December 31, 2013, the Company had an accumulated deficit of $10,668,408.  The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability to raise equity or debt financing, and the attainment of profitable operations from the Company's planned business. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
	In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.
	The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note_3_Summary_of_Significant_

Note 3 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 3 - Summary of Significant Accounting Policies	'
	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Accounting Basis
	The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States.  The Company has elected a December 31 fiscal year end.
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. There were no cash equivalents as of December 31, 2013 or 2012.
	Concentration of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash.   Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States.  The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $991,397 and $0 of cash balances in excess of federally insured limits at December 31, 2013 and 2012, respectively.
	Property and Equipment
	Property and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment:
	Description		Useful Lives
	Computers		3 years
	Equipment		5 years
	Fair Value of Financial Instruments
	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments.  ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:
	Description		Level 1		Level 2		Level 3		Total
	Derivative Liability		$	-	$	-	$	-	$	-
	Total		$	-	$	-	$	-	$	-
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2012, on a recurring basis:
	Description		Level 1		Level 2		Level 3		Total
	Derivative Liability		$	-	$	-	$	-5,687,262	$	-5,687,262
	Total		$	-	$	-	$	-5,687,262	$	-5,687,262
	A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a description of the valuation methodology used to measure fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.
	Derivative Liability:     Market prices are not available for the Company's warrants nor are market prices of similar warrants available. The Company assessed that the fair value of this liability approximates its carrying value since carrying value has been adjusted to fair value.
	The method described above may produce a current fair value calculation that may not be indicative of net realizable value or reflective of future fair values. If a readily determined market value became available or if actual performance were to vary appreciably from assumptions used, assumptions may need to be adjusted, which could result in material differences from the recorded carrying amounts. The Company believes its method of determining fair value is appropriate and consistent with other market participants. However, the use of different methodologies or different assumptions to value certain financial instruments could result in a different estimate of fair value.
	The following tables present the fair value of financial instruments as of December 31, 2013, by caption on the condensed balance sheet and by ASC 820 valuation hierarchy described above.
		Stock Warrant
	Level 3 Reconciliation:	Derivative
	Level 3 assets and liabilities at December 31, 2012	$	-5,687,262
	Purchases, sales, issuances and settlements (net)		5,687,262
	Total level 3 assets and liabilities at December 31, 2013	$	-
	Derivative Financial Instruments
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.
	Research and Development Costs
	The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $841,502 and $939,296 during the years ended December 31, 2013 and 2012, respectively.
	Stock-Based Compensation
	The Company follows the provisions of ASC 718 which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values.  The Company uses the Black-Scholes pricing model for determining the fair value of stock based compensation.
	Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.
	Income Taxes
	The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
	In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.
	The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
	Basic and Diluted Net income (Loss) per Share
	The Company computes net income (loss) per share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
	For the years ended December 31, 2013 and 2012, all of the Company’s potentially dilutive securities (warrants, options, and convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive.  The total number of potentially dilutive shares that were excluded was 18,162,608 and 12,814,874 at December 31, 2013 and 2012, respectively.
	Deemed Dividend on Warrant Amendment
	During the year ended December 31, 2013, the Company amended the terms of its Class A, B, C and PAW Warrants with certain investors who held warrants to purchase 11,364,453 shares of our common stock to extend the terms of the Warrants such that none of the Warrants expire before the 5th anniversary of the date on which the Common Stock begins public trading on a national securities exchange.   The modification of the expiration date of the warrant resulted in a deemed dividend to warrant holders of approximately, $2,445,621 which was calculated as the difference between fair value of the warrants immediately before and after the modification using the Black-Scholes option pricing model.  The deemed dividends have been included in the calculation of the net loss attributable to common stockholders of approximately $4,402,493 or $0.34 per share, the year ended December 31, 2013.  The deemed dividends are excluded from our net loss (from operating activities) of approximately $4,402,493, or $0.34 per share, for the year ended December 31, 2013.
	Recent Accounting Pronouncements
	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is it expected to have a material impact on the Company’s financial position, or statements.

Note_4_Equipment

Note 4 - Equipment	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 4 - Equipment	'
	NOTE 4 – EQUIPMENT
	Property and equipment consists of the following as of December 31, 2013 and 2012. Depreciation expense was $144 and $1,265 for the years ended December 31, 2013 and 2012, respectively.
		2013		2012
	Computer equipment	$	5,390	$	5,390
	Accumulated Depreciation		-5,390		-5,246
	Net Book Value	$	-	$	144

Note_5_Accrued_Liabilities

Note 5 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 5 - Accrued Liabilities	'
	NOTE 5 – ACCRUED LIABILITIES
	Pursuant to the applicable Codification literature, the Company has concluded it is probable that it will pay $85,738 in liquidated damages pursuant to the registration rights clause in certain of the securities sold in fiscal years 2008 and 2009, the Company was required to file a registration statement by January 27, 2009. The Company failed to do so until April 7, 2009, resulting in liquidated damages of 2% per month of the gross proceeds, which approximated $1.8 million as of that date. During the year ended December 31, 2009, the Company’s registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.

Note_6_Note_Payable

Note 6 - Note Payable	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 6 - Note Payable	'
	NOTE 6 – NOTE PAYABLE
	In January 2012, the Company received cash pursuant to a short-term promissory note with a related party. The note was repaid in full in February 2012. The note did not bear interest.
	On September 27, 2012, the Company received $55,075 in cash pursuant to a short-term promissory note with a related party. The note did not bear interest and was due on demand. In December 2012, the balance on the note was repaid in full.
	In January 2013, the Company received $25,000 in cash pursuant to a short-term promissory note with a related party. In March 2013 the Company received $5,000 in cash pursuant to a short-term promissory note with the same related party. The note did not bear interest.  The Company assessed the imputed interest and found the balance to be immaterial. In April 2013, the balance on the note was repaid in full.

Note_7_Derivative_Liability_an

Note 7 - Derivative Liability and Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 7 - Derivative Liability and Fair Value Measurements	'
	NOTE 7 – DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS
	The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with its Series A Preferred Stock and associated warrants to purchase common stock.  On May 7, 2013, the Company amended its Certificate of Incorporation to eliminate anti-dilution price protection from its Series A Preferred Stock and associated derivative liability.  On January 1, 2009, the Company adopted ASC Topic No. 815-40 which defines determining whether an instrument (or embedded feature) is solely indexed to an entity’s own stock. As of January 1, 2009, the Company had issued 3,572,714 warrants which have exercise prices that are subject to “reset” provisions in the event the Company subsequently issues common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than $0.85 and $1.27, respectively. If these provisions are triggered, the exercise price of all of those warrants will be reduced.  As a result, the warrants are not considered to be solely indexed to the Company’s own stock and are not afforded equity treatment.
	As a result, on January 1, 2009, 3,572,714 of the Company’s outstanding warrants containing exercise price reset provisions, originally classified as permanent equity, were reclassified to derivative liability. These warrants had exercise prices ranging from $0.85 - $1.27 and expire starting in December 2013. As of January 1, 2009, the fair value of these warrants of $1,676,633 was recognized and resulted in a cumulative effect adjustment to retained earnings of $43,808. On May 7, 2013, the Company effectively removed the derivative provision from the warrants and convertible debt and valued the derivatives market to market as of that date. The derivative liability was then converted to additional paid-in-capital. The change in fair value during the years ended December 31, 2013 and 2012 of $(3,926) and $(8,154), respectively, is recorded as a derivative loss in the accompanying Statements of Operations.
	During the year ended December 31, 2012, the Company issued 1,313,533 warrants which were attached to 1,116 shares of convertible preferred stock. The Company issued an additional 757,223 warrants as stock offering costs to the Company’s placement agent. The combined fair market value of the derivative liability associated with these issuances at the date of issuance was $301,800.
	During the year ended December 31, 2011, the Company issued 1,704,884 warrants which were attached to 1,449 shares of convertible preferred stock.  The Company issued an additional 1,022,931 warrants as stock offering costs to the Company’s placement agent.  The combined fair market value of the derivative liability associated with these issuances at the date of issuance was $2,184,753.
	During the year ended December 31, 2010, the Company issued 676,775 warrants which were attached to 575 shares of convertible preferred stock.  The Company issued an additional 391,353 warrants as stock offering costs to the Company’s placement agent.  The Combined fair market value of the derivative liability associated with these issuances for the year ended December 31, 2010 was $852,346.
	During the year ended December 31, 2009, the Company issued 953,370 warrants which were attached to 810 shares of convertible preferred stock.  The Company issued an additional 286,011 warrants as stock offering costs to the Company’s placement agent.  The Combined fair market value of the derivative liability associated with these issuances for the year ended December 31, 2009 was $988,552.
	The Company classifies the fair value of these warrants under level three of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a lattice model that values the compound embedded derivatives based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The embedded derivatives that were analyzed and incorporated into the model included the conversion feature with the full ratchet reset, and the redemption options.
	The Series A Preferred Derivatives were valued using the following assumptions:
	·         The Company was 3 months from being publicly traded and the Company/Holder would convert the Preferred Stock based on 200% of the adjusted conversion price;
	·         The Preferred maturity date used was 7 years following the Company being publicly traded (rolling 6 years from the Valuation Date);
	·         The stock price of $0.85 was used as the fair value of the common stock based on the previous common stock transaction;
	·         The projected volatility curve was based on the average of 15 comparable biotech companies historical volatility:
	·         The Holder would automatically convert at a stock price of $1.70 if the Company was not in default;
	·         The Holder would convert on a quarterly basis in equal amounts to maturity if in the money; and
	·         Capital raising events would occur annually, generating reset events based on pricing not greater than 100% of market.
	The warrants were valued at issuance and marked to market quarterly for the period 2009 through December 2011. The five-year warrants are options to purchase shares of common stock at an exercise price of $0.85 per share and $1.27, subject to adjustments. The following assumptions were used for the valuation of the derivative:
	·         The stock price of $0.85 was used as the fair value of the common stock based on the previous common stock transaction;
	·         The projected volatility curve was based on the average of comparable companies as provided in the Preferred assumptions above;
	·         The Holder would exercise the warrant at maturity if the stock price was above the exercise price;
	·         The Holder would exercise the warrant at target prices starting at $1.58 for the Investor Warrants and $1.40 for the Placement Agent Warrants, and lowering such target as the warrants approached maturity.
	·         The Holder would automatically convert all of the shares at a stock price of $1.58 for the Investor Warrants and $1.40 for the Placement Agent Warrants;
	·         The Holder would convert on a quarterly basis in amounts not to exceed the average quarters trading volume based on historical performance, assuming the volume would increase by 5% each quarter; and
	·         Capital raising events would occur annually, generating reset events based on pricing not greater than 100% of market for the Placement Agent Warrants and for the Investor Warrants the reset would be 150% of the Preferred.
	The Company determined the fair value of the preferred stock to be $0 and $3,182,380 and the fair value of the warrants to be $0 and $2,504,879 at December, 2013 and December 31, 2012, respectively.
	The following shows the changes in the level three liability measured on a recurring basis from December 31, 2012 through December 31, 2013:
	Balance, December 31, 2012	$	5,687,262
	Derivative loss		3,923
	Derivative liability for warrants removed during the period		-5,691,185
	Balance, December 31, 2013	$	-

Note_8_Capital_Stock

Note 8 - Capital Stock	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 8 - Capital Stock	'
	NOTE 8 – CAPITAL STOCK
	The Series A Convertible Preferred Stock (“Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on November 26, 2008, and as last amended on July 17, 2013, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series A Preferred Stock. The shares of Preferred Stock are fully paid and non-assessable. As of December 31, 2013, the Company has issued 3,255 shares of Series A Preferred Stock.
	Rank
	The Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Preferred Stock or not specifically ranking by its terms senior to or on parity with the Preferred Stock, (ii) on parity with any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Preferred Stock, and (iii) junior to any class or series of capital stock specifically ranking by its terms senior to the Preferred Stock, in each case, as to payment of dividends or as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The approval of the holders of a majority of the Preferred Stock is required in order for the Company to issue any capital stock with rights on parity with or senior to the Preferred Stock.
	Dividends
	The holders of the Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Preferred Stock. Such dividends are payable in shares of common stock, semiannually on the last business day of February and August of each year (each a “Dividend Payment Date”), commencing in February 2009 with respect to the period from issuance through such date. The holders of the Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 1,177 shares of common stock ($.85 per share) for each share of Preferred Stock.
	The Conversion Price is subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock. No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 300% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least two-thirds of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Preferred Stock that would adversely affect the Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	Series B Convertible Preferred Stock
	The Series B Convertible Preferred Stock (“Series B Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on September 2, 2011, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series B Preferred Stock. The shares of Series B Preferred Stock are fully paid and non-assessable. As of December 31, 2013, the Company had issued 2,146 shares of Series B Preferred Stock.
	Rank
	The Series B Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Series B Preferred Stock or not specifically ranking by its terms senior to or on parity with the Series B Preferred Stock, (ii) on parity with any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Series B Preferred Stock, and (iii) junior to Series A Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary.
	Dividends
	The holders of the Series B Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Series B Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series B Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series B Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Series B Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series B Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series B Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series B Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Series B Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 1,177 shares of common stock ($.85 per share) for each Share of Series B Preferred Stock.
	The Conversion Price is subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock but does not contain the same price protection ratchets as the Series A Preferred Stock. No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 200% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least a majority of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Series B Preferred Stock that would adversely affect the Series B Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Series B Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Series B Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, after payment to the holders of Series A Preferred Stock the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	Series C Convertible Preferred Stock
	The Series C Convertible Preferred Stock (“Series C Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on March 12, 2013, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series C Preferred Stock. The shares of Series C Preferred Stock are fully paid and non-assessable. As of December 31, 2013, the Company had issued 3,380 shares of Series C Preferred Stock.
	Rank
	The Series C Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Series C Preferred Stock or not specifically ranking by its terms senior to or on parity with the Series C Preferred Stock, (ii) on parity with the Series B Preferred Stock and any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Series C Preferred Stock, and (iii) junior to Series A Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary.
	Dividends
	The holders of the Series C Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Series C Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series C Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series C Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Series C Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series C Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Series C Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 800 shares of common stock ($1.25 per share) for each Share of Series C Preferred Stock.
	The Conversion Price is subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock.  No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 300% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least a majority of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Series C Preferred Stock that would adversely affect the Series C Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Series C Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Series C Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, after payment to the holders of Series A Preferred Stock the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	During the year ended December, 2013, the Company issued 3,380 shares of its par value $0.10 Series C Convertible Preferred Stock for cash at $1,000 per share.
	During the year ended December 31, 2012, the Company issued 1,116 shares of its par value $0.10 convertible Series B preferred stock for cash at $1,000 per share.
	During the year ended December 31, 2011, the Company issued 419 shares of its par value $0.10 Series A Convertible Preferred Stock and 1,030 shares of its par value $0.10 Series B Convertible Preferred Stock, for a total of 1,449 shares of Preferred Stock, for cash at $1,000 per share.
	During the year ended December 31, 2010, the Company issued 575 shares of its par value $0.10 Series A Convertible Preferred Stock for cash at $1,000 per share.
	During the year ended December 31, 2009, the Company issued 810 shares of its par value $0.10 Series A Convertible Preferred Stock at $1,000 per share.
	On November 25, 2008, the Company issued 562 shares of its par value $0.10 Series A Convertible Preferred Stock for cash at $1,000 per share.
	On November 25, 2008, the Company issued 890 shares of its par value $0.10 Series A Convertible Preferred Stock to extinguish bridge debt financing totaling $889,875.
	Between January 24 and April 15, 2008, the Company issued 1,082,500 common shares of the Company at $0.85 per common share in accordance with the Bridge Note agreements.
	As of December 31, 2013 and 2012, the Company has accrued $1,353,961 and $861,872 and has not paid any dividends, respectively.
	Common Stock
	During year ended December 31, 2013, the Company issued 40,000 shares of common stock, for services performed at $0.85 per share. The Chairman of the Audit Committee also received 30,000, 40,000 and 40,000 restricted shares of Common Stock on December 28, 2010, December 22, 2011 and February 20, 2013, in consideration of consulting and accounting services as chairman of the Company’s Audit Committee. The 40,000 issued in the quarter ended March 31, 2013 were not issued until the current quarter and were booked initially as a stock payable in the amount of $34,000 valued at the stock price on February 20, 2013 of $0.85. As of December 31, 2013, stock payable was $-0-. He will be reimbursed for reasonable expenses incurred, however will not receive any other cash compensation.
	During the year ended December 31, 2012, the Company issued 7,500 shares of common stock to a consultant of the Company in exchange for services valuing $16,000. The shares were valued based on the last sale price of $0.85 per share. The difference of $9,625 was recognized as a gain.
	During the year ended December 31, 2011, the Company issued 640,000 shares of common stock to officers and consultants in exchange for services provided. The shares were valued based on the price of $0.85 per share and the Company recognized $151,000 in salaries and wages, $289,000 in consulting expense, and extinguished $104,000 in accrued officer salary.
	On September 16, 2010 the Company issued 400,000 shares of common stock to officers and consultants of the Company in exchange for services provided. The shares were valued based on the price of $0.85 per share and the Company recognized $340,000 in consulting expense.
	On December 28, 2010 the Company issued 450,000 shares of common stock to officers and consultants of the Company in exchange for services provided. The shares were valued based on the price of $0.85 per share and the Company recognized $382,500 in consulting expense.

Note_9_Warrants

Note 9 - Warrants	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 9 - Warrants	'
	NOTE 9 – WARRANTS
	A summary of the status of the Company's warrants as of December 31, 2013 and changes from inception through December 31, 2012 are presented below:
	Date of	Warrant	Exercise	Value if
	Issuance	Shares	Price	Exercised
	11/25/08	1,259,639	1.27	$         1,599,742
	11/25/08	530,314	0.85	450,767
	11/26/08	449,220	1.27	570,509
	Outstanding at 12/31/2008	2,239,173	1.17	2,621,018
	3/5/09	347,215	1.27	440,963
	3/5/09	104,165	0.85	88,540
	4/1/09	17,655	1.27	22,422
	4/1/09	5,296	0.85	4,502
	6/17/09	235,400	1.27	298,958
	6/17/09	70,620	0.85	60,027
	7/23/09	58,850	1.27	74,740
	7/23/09	35,310	0.85	30,014
	8/20/09	58,850	1.27	74,740
	9/9/09	235,400	1.27	298,958
	9/9/09	70,620	0.85	60,027
	Outstanding at 12/31/2009	3,478,554	1.17	4,074,909
	2/11/10	29,425	1.27	37,370
	2/11/10	17,655	0.85	15,007
	5/21/10	29,425	1.27	37,370
	5/21/10	17,655	0.85	15,007
	8/10/10	88,275	1.27	112,109
	8/10/10	52,965	0.85	45,020
	9/15/10	264,825	1.27	336,328
	9/15/10	52,965	0.85	45,020
	9/24/10	105,930	0.85	90,041
	10/27/10	147,125	1.27	186,849
	10/27/10	73,563	0.85	62,529
	11/19/10	117,700	1.27	149,479
	11/24/10	70,620	0.85	60,027
	Outstanding at 12/31/2010	4,546,682	1.16	5,267,063
	1/26/11	117,700	1.27	149,479
	1/26/11	60,027	1.27	76,234
	1/26/11	106,636	0.85	90,641
	3/15/11	58,850	1.27	74,740
	3/15/11	35,310	0.85	30,014
	4/6/11	70,620	0.85	60,027
	4/6/11	117,700	1.27	149,479
	6/8/11	51,200	0.85	43,520
	6/8/11	85,333	1.27	108,373
	6/20/11	17,655	0.85	15,007
	6/20/11	29,425	1.27	37,370
	7/26/11	23,540	1.27	29,896
	7/26/11	14,124	0.85	12,005
	8/22/11	29,424	1.27	37,368
	8/22/11	17,655	0.85	15,007
	8/30/11	105,930	0.85	90,041
	9/2/11	176,550	1.27	224,219
	9/9/11	58,850	1.27	74,740
	9/9/11	35,310	0.85	30,014
	9/22/11	441,375	1.27	560,546
	9/22/11	264,825	0.85	225,101
	11/2/11	141,240	0.85	120,054
	11/2/11	235,400	1.27	298,958
	11/23/11	35,310	0.85	30,014
	11/23/11	58,850	1.27	74,740
	12/27/11	127,116	0.85	108,049
	12/27/11	211,860	1.27	269,062
	Outstanding at 12/31/11	7,274,497	1.14	8,301,757
	1/31/12	117,700	1.27	149,479
1/31/12	70,620	0.85	60,027
2/2/12	76,505	1.27	97,161
2/2/12	45,903	0.85	39,018
2/10/12	58,850	1.27	74,740
2/10/12	35,310	0.85	30,014
4/10/12	41,666	0.85	35,416
4/10/12	69,443	1.27	88,193
5/11/12	35,310	0.85	30,014
5/11/12	58,850	1.27	74,740
6/4/12	35,310	0.85	30,014
6/4/12	58,850	1.27	74,740
6/19/12	35,310	0.85	30,014
6/19/12	58,850	1.27	74,740
7/24/12	44,138	1.27	56,055
7/24/12	58,850	1.27	74,740
7/24/12	30,896	0.85	26,262
7/30/12	235,400	1.27	298,958
7/30/12	141,240	0.85	120,054
8/28/12	258,352	1.27	328,107
8/28/12	155,011	0.85	131,759
10/18/12	158,895	1.27	201,797
10/18/12	95,337	0.85	81,036
11/26/12	58,850	1.27	74,740
11/27/12	35,310	0.85	30,014
Outstanding at 12/31/12	9,345,253	1.14	10,613,584
2/28/13	400,000	0.85	340,000
3/1/13	(1,625,192)	0.85	(1,381,413)
3/1/13	1,625,192	0.85	1,381,413
3/13/13	800,000	1.88	1,500,000
3/13/13	480,000	0.85	408,000
6/19/13	127,200	0.85	108,120
6/19/13	212,000	1.88	397,500
7/24/13	60,000	1.88	112,500
7/24/13	100,000	1.88	187,500
7/24/13	96,000	1.25	120,000
8/29/13	80,000	1.88	150,000
8/29/13	48,000	1.25	60,000
8/29/13	(48,000)	1.25	(60,000)
10/24/13	61,764	0.85	52,499
10/24/13	10,588	0.85	9,000
10/24/13	1,552,840	0.85	1,319,914
10/24/13	(1,552,840)	0.85	(1,319,914)
10/24/13	10,000	1.25	12,500
10/24/13	38,000	1.25	47,500
11/8/13	100,000	1.88	187,500
11/8/13	60,000	1.25	75,000
12/18/13	78,000	1.25	97,500
12/18/13	78,000	1.25	97,500
12/18/13	15,000	0.85	12,750
12/18/13	1,537,840	0.85	1,307,164
Outstanding at 12/31/13	13,689,648	1.13	15,849,164
The warrants were issued in connection with the Preferred Stock Offering and were valued using the Lattice model and accounted for as described in Note 9.
As of December 1, 2013, the Company’s Board of Directors extended the terms of all outstanding warrants, some of which were set to expire in 2014 or 2015, such that none of the warrants expire before the fifth anniversary of the date on which the Company’s common stock begins trading on a national securities exchange, the OTC Bulletin Board or OTC Pink. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 and $1.27 stock price, $0.85 and $1.27 exercise price, the Warrants expire before the 5th anniversary of the date on which the Common Stock begins public trading on a national securities exchange, 107.73% volatility, .10% to 1.43% risk free rate.
During the period ended December 31, 2013, the Company extended the exercise period of 3,226,032 Class A warrants with an exercise prices of $0.85 to expire on the fifth anniversary of the next registration statement to be filed. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 to 7 years to maturity, 107% to 112% volatility, .96% to 2.26% risk free rate.  As a result of the modification the Company recognized a loss on equity modification of $156,477.
On February 20, 2013, the Company issued 400,000 warrants to its vendor for curcumin. The warrants have an exercise price of $0.85 per share and have a life of five years from the effective date of a registration statement.  The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .85% risk free rate. The Company recorded expense of $339,997 related to these warrants for the year ended December 31, 2013.
During the period ended December 31, 2013, the Company issued 1,087,552 warrants as stock offering costs to the Company’s placement agent. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants.
The Company will issue cash or warrants as stock offering costs.  The Company recognizes the cost upon completion of the share purchase.  Warrants are valued and recorded using the lattice model.  Total stock issuance costs for December 31, 2013 and 2012 were $550,326 and $221,175, respectively.
The holders of the Series C Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% and a liquidation preference, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series C Preferred Stock but junior to the Series A Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series C Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
Dividends on the Series C Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series B Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series C Preferred Stock have been, or contemporaneously are, declared and paid in full.
The Company’s balance, for dividends payable, as of December 31, 2013 and 2012 is, $1,353,960 and $861,872, respectively.

Note_10_Stock_Options

Note 10 - Stock Options	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 10 - Stock Options	'
	NOTE 10 – STOCK OPTIONS
	The Company’s 2009 Employee Stock Incentive Plan (the “2009 Plan”) was adapted by the Company’s Board of Directors on February 9, 2009 in order to motivate participants by means of stock options and restricted stock to achieve the Company’s long-term performance goals and enable our employees, officers, directors and consultants to participate in our long term growth and financial success. The 2009 Plan, as amended on February 13, 2013, which is administered by our Board of Directors, authorizes the issuance of a maximum of 1,000,000 shares of our common stock, plus on a yearly basis an additional amount equal to 10% of the amount of shares issued during the prior year.  Thus, as of January 1, 2014, a maximum of 1,047,000 shares were authorized for issuance under the 2009 Plan.  Employee options shall be deemed Incentive Stock Options (as defined in the 2009 Option Plan) to the maximum extent permitted by Section 422 of the Internal Revenue Code including a five-year limit on exercise for 10% or greater stockholders with any excess grant to the above individuals over the limits set by Section 422 being Non-Qualified Stock Options as defined in the 2009 Option Plan. Both the Incentive Stock Options or any Non-Qualified Stock Options must be granted at an exercise price of not less than the fair market value of shares of common stock at the time the option is granted and Incentive Stock Options granted to 10% or greater stockholders must be granted at an exercise price of not less than 110% of the fair market value of the shares on the date of grant.
	If any award under the 2009 Plan terminates, expires unexercised, or is cancelled, the shares of common stock that would otherwise have been issuable pursuant thereto will be available for issuance pursuant to the grant of new awards. The 2009 Plan will terminate on February 9, 2019. As of December 31, 2013, the following options had been granted under the plan:
	1On July 12, 2010 the Company issued 100,000 options to a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of ten years. The options vest as follows: one third on the date of grant, one third on each of the second and third anniversary dates from the date of grant. The Company valued these options using the Black-Scholes option pricing model totaling $84,300 under the following assumptions: $0.85 stock price, $0.85 stock price, 10 years to maturity, 400% volatility, 2.02% risk free rate.  The Company recorded amortization expense of $4,952 and $16,772 related to these options for the years ended December 31, 2013 and 2011.
	2On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services to be rendered during 2013. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.  The Company recorded amortization expense of $50,928 related to these options for the year ended December 31, 2013.
	3On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services rendered during 2012. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. The Company recorded amortization expense of $50,941 related to these options for the year ended December 31, 2013.
	4On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services to be rendered during 2013. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. The Company recorded amortization expense of $50,928 related to these options for the year ended December 31, 2013.
	5On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services rendered during 2012. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. The Company recorded amortization expense of $50,928 related to these options for the year ended December 31, 2013.
	6On February 20, 2013 the Company issued 82,400 incentive stock options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $70,040 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate. The Company recorded amortization expense of $69,918 related to these options for the year ended December 31, 2013.
	7On February 20, 2013 the Company issued 117,600 options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $99,960 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate. The Company recorded amortization expense of $99,786 related to these options for the year ended December 31, 2013.
	8On February 20, 2013 the Company issued 30,000 options to its law firm under the 2009 Plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $25,500 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .88% risk free rate. The Company recorded amortization expense of $25,471 related to these options for the year ended December 31, 2013.
	The Company has recorded amortization expense of $667,449 and $16,772 related to these options for the year ended December 31, 2013 and 2012.

Note_11_Income_Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 11 - Income Taxes	'
	NOTE 11 – INCOME TAXES
	The Company’s provision for income taxes was $0 for the years ended December 31, 2013 and 2012 respectively since the Company incurred net operating losses which have a full valuation allowance through December 31, 2012.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company’s opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a full valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is calculated by multiplying a 39% marginal tax rate by the cumulative Net Operating Loss (“NOL”) of $7,436,707. The total valuation allowance is equal to the total deferred tax asset.  The valuation allowance increased by $488,084 from $2,412,232 to $2,900,316 for the year ended December 31, 2013.
	The tax effects of significant items comprising the Company's net deferred taxes as of December 31, 2013 and 2012 were as follows:
		2013		2012
	Cumulative NOL	$	7,436,707	$	6,185,210
	Deferred Tax assets:
	Net operating loss carry forwards		2,900,316		2,412,232
	Valuation allowance		-2,900,316		-2,412,232
		$	-	$	-
	The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates of 39% to pretax income from continuing operations for the years ended December 31, 2013 and 2012 due to the following:
		2013		2012
	Income tax benefit at U. S. federal statutory rates:	$	-763,180	$	-511,264
	Stock-based compensation		273,565		9,027
	Derivative liability		1,531		3,180
	Change in valuation allowance		488,084		499,057
		$	-	$	-
	The Company adopted the provisions of ASC 740 at the beginning of fiscal year 2008. As a result of this adoption, the Company has not made any adjustments to deferred tax assets or liabilities.  The Company did not identify any material uncertain tax positions on returns that have been filed or that will be filed.  The Company did not recognize any interest or penalties for unrecognized tax benefits during the years ended December 31, 2013 and 2012, nor were any interest or penalties accrued as of December 31, 2013.
	The Company has filed income tax returns in the United States and Florida. All tax years prior to 2009 are closed by expiration of the statute of limitations.   The years ended December 31, 2013, 2012, and 2011 is open for examination.
	The Company’s net state and federal operating loss carry forwards of approximately $7,436,707 expire in various years beginning in 2027 and carrying forward through 2033.
	The Company has had numerous transactions in its common stock.  Such transactions may have resulted in a change in the Company's ownership, as defined in the Internal Revenue Code Section 382.  Such change may result in an annual limitation on the amount of the Company's taxable income that may be offset with its net operating loss carry forwards.  The Company has not evaluated the impact of Section 382, if any, on its ability to utilize its net operating loss carry forwards in future years.

Note_12_Related_Party_Transact

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 12 - Related Party Transactions	'
	NOTE 12 – RELATED PARTY TRANSACTIONS
	On January 31, 2013, the Company signed a demand promissory note with a related party. The principal sum of the note was $25,000, bearing no interest.
	On March 4, 2013, the Company signed a demand promissory note with a related party. The principal sum of the note was $5,000, bearing no interest.
	On March 1, 2013, the Company paid the principal sum of $30,000 on demand promissory notes

Note_13_Subsequent_Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 13 - Subsequent Events	'
	NOTE 13 – SUBSEQUENT EVENTS
	In accordance with ASC 855-10 Company management reviewed all material events through the date of this report and had no material subsequent events to report.

Note_3_Summary_of_Significant_1

Note 3 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note_3_Summary_of_Significant_2

Note 3 - Summary of Significant Accounting Policies: Accounting Basis (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Accounting Basis	'
	Accounting Basis
	The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States.  The Company has elected a December 31 fiscal year end.

Note_3_Summary_of_Significant_3

Note 3 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. There were no cash equivalents as of December 31, 2013 or 2012.

Note_3_Summary_of_Significant_4

Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash.   Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States.  The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $991,397 and $0 of cash balances in excess of federally insured limits at December 31, 2013 and 2012, respectively.

Note_3_Summary_of_Significant_5

Note 3 - Summary of Significant Accounting Policies: Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Property and Equipment	'
	Property and Equipment
	Property and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment:
	Description	Useful Lives
	Computers	3 years
	Equipment	5 years

Note_3_Summary_of_Significant_6

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments.  ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:
	Description		Level 1		Level 2		Level 3		Total
	Derivative Liability		$	-	$	-	$	-	$	-
	Total		$	-	$	-	$	-	$	-
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2012, on a recurring basis:
	Description		Level 1		Level 2		Level 3		Total
	Derivative Liability		$	-	$	-	$	-5,687,262	$	-5,687,262
	Total		$	-	$	-	$	-5,687,262	$	-5,687,262
	A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a description of the valuation methodology used to measure fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.
	Derivative Liability:     Market prices are not available for the Company's warrants nor are market prices of similar warrants available. The Company assessed that the fair value of this liability approximates its carrying value since carrying value has been adjusted to fair value.
	The method described above may produce a current fair value calculation that may not be indicative of net realizable value or reflective of future fair values. If a readily determined market value became available or if actual performance were to vary appreciably from assumptions used, assumptions may need to be adjusted, which could result in material differences from the recorded carrying amounts. The Company believes its method of determining fair value is appropriate and consistent with other market participants. However, the use of different methodologies or different assumptions to value certain financial instruments could result in a different estimate of fair value.
	The following tables present the fair value of financial instruments as of December 31, 2013, by caption on the condensed balance sheet and by ASC 820 valuation hierarchy described above.
		Stock Warrant
	Level 3 Reconciliation:	Derivative
	Level 3 assets and liabilities at December 31, 2012	$	-5,687,262
	Purchases, sales, issuances and settlements (net)		5,687,262
	Total level 3 assets and liabilities at December 31, 2013	$	-

Note_3_Summary_of_Significant_7

Note 3 - Summary of Significant Accounting Policies: Derivative Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Derivative Financial Instruments	'
	Derivative Financial Instruments
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.

Note_3_Summary_of_Significant_8

Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Research and Development Costs	'
	Research and Development Costs
	The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $841,502 and $939,296 during the years ended December 31, 2013 and 2012, respectively.

Note_3_Summary_of_Significant_9

Note 3 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Stock-based Compensation	'
	Stock-Based Compensation
	The Company follows the provisions of ASC 718 which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values.  The Company uses the Black-Scholes pricing model for determining the fair value of stock based compensation.
	Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.

Recovered_Sheet1

Note 3 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
	In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.
	The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Recovered_Sheet2

Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Basic and Diluted Net Income (loss) Per Share	'
	Basic and Diluted Net income (Loss) per Share
	The Company computes net income (loss) per share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
	For the years ended December 31, 2013 and 2012, all of the Company’s potentially dilutive securities (warrants, options, and convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive.  The total number of potentially dilutive shares that were excluded was 18,162,608 and 12,814,874 at December 31, 2013 and 2012, respectively.

Recovered_Sheet3

Note 3 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is it expected to have a material impact on the Company’s financial position, or statements.

Recovered_Sheet4

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Fair Value, Liabilities Measured on Recurring Basis	'
	Description	Level 1		Level 2		Level 3		Total
	Derivative Liability	$	-	$	-	$	-	$	-
	Total	$	-	$	-	$	-	$	-
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2012, on a recurring basis:
	Description	Level 1		Level 2		Level 3		Total
	Derivative Liability	$	-	$	-	$	-5,687,262	$	-5,687,262
	Total	$	-	$	-	$	-5,687,262	$	-5,687,262

Recovered_Sheet5

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Level 3 Valuation Reconciliation	'
		Stock Warrant
	Level 3 Reconciliation:	Derivative
	Level 3 assets and liabilities at December 31, 2012	$	-5,687,262
	Purchases, sales, issuances and settlements (net)		5,687,262
	Total level 3 assets and liabilities at December 31, 2013	$	-

Note_4_Equipment_Property_Plan

Note 4 - Equipment: Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Property, Plant and Equipment	'
		2013		2012
	Computer equipment	$	5,390	$	5,390
	Accumulated Depreciation		-5,390		-5,246
	Net Book Value	$	-	$	144

Note_7_Derivative_Liability_an1

Note 7 - Derivative Liability and Fair Value Measurements: Fair value of the preferred stock (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Fair value of the preferred stock	'
	Balance, December 31, 2012	$	5,687,262
	Derivative loss		3,923
	Derivative liability for warrants removed during the period		-5,691,185
	Balance, December 31, 2013	$	-

Note_9_Warrants_Schedule_of_St

Note 9 - Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Schedule of Stockholders' Equity Note, Warrants or Rights	'
	Date of	Warrant	Exercise	Value if
	Issuance	Shares	Price	Exercised
	11/25/08	1,259,639	1.27	$         1,599,742
	11/25/08	530,314	0.85	450,767
	11/26/08	449,220	1.27	570,509
	Outstanding at 12/31/2008	2,239,173	1.17	2,621,018
	3/5/09	347,215	1.27	440,963
	3/5/09	104,165	0.85	88,540
	4/1/09	17,655	1.27	22,422
	4/1/09	5,296	0.85	4,502
	6/17/09	235,400	1.27	298,958
	6/17/09	70,620	0.85	60,027
	7/23/09	58,850	1.27	74,740
	7/23/09	35,310	0.85	30,014
	8/20/09	58,850	1.27	74,740
	9/9/09	235,400	1.27	298,958
	9/9/09	70,620	0.85	60,027
	Outstanding at 12/31/2009	3,478,554	1.17	4,074,909
	2/11/10	29,425	1.27	37,370
	2/11/10	17,655	0.85	15,007
	5/21/10	29,425	1.27	37,370
	5/21/10	17,655	0.85	15,007
	8/10/10	88,275	1.27	112,109
	8/10/10	52,965	0.85	45,020
	9/15/10	264,825	1.27	336,328
	9/15/10	52,965	0.85	45,020
	9/24/10	105,930	0.85	90,041
	10/27/10	147,125	1.27	186,849
	10/27/10	73,563	0.85	62,529
	11/19/10	117,700	1.27	149,479
	11/24/10	70,620	0.85	60,027
	Outstanding at 12/31/2010	4,546,682	1.16	5,267,063
	1/26/11	117,700	1.27	149,479
	1/26/11	60,027	1.27	76,234
	1/26/11	106,636	0.85	90,641
	3/15/11	58,850	1.27	74,740
	3/15/11	35,310	0.85	30,014
	4/6/11	70,620	0.85	60,027
	4/6/11	117,700	1.27	149,479
	6/8/11	51,200	0.85	43,520
	6/8/11	85,333	1.27	108,373
	6/20/11	17,655	0.85	15,007
	6/20/11	29,425	1.27	37,370
	7/26/11	23,540	1.27	29,896
	7/26/11	14,124	0.85	12,005
	8/22/11	29,424	1.27	37,368
	8/22/11	17,655	0.85	15,007
	8/30/11	105,930	0.85	90,041
	9/2/11	176,550	1.27	224,219
	9/9/11	58,850	1.27	74,740
	9/9/11	35,310	0.85	30,014
	9/22/11	441,375	1.27	560,546
	9/22/11	264,825	0.85	225,101
	11/2/11	141,240	0.85	120,054
	11/2/11	235,400	1.27	298,958
	11/23/11	35,310	0.85	30,014
	11/23/11	58,850	1.27	74,740
	12/27/11	127,116	0.85	108,049
	12/27/11	211,860	1.27	269,062
	Outstanding at 12/31/11	7,274,497	1.14	8,301,757
	1/31/12	117,700	1.27	149,479
	1/31/12	70,620	0.85	60,027
	2/2/12	76,505	1.27	97,161
2/2/12	45,903	0.85	39,018
2/10/12	58,850	1.27	74,740
2/10/12	35,310	0.85	30,014
4/10/12	41,666	0.85	35,416
4/10/12	69,443	1.27	88,193
5/11/12	35,310	0.85	30,014
5/11/12	58,850	1.27	74,740
6/4/12	35,310	0.85	30,014
6/4/12	58,850	1.27	74,740
6/19/12	35,310	0.85	30,014
6/19/12	58,850	1.27	74,740
7/24/12	44,138	1.27	56,055
7/24/12	58,850	1.27	74,740
7/24/12	30,896	0.85	26,262
7/30/12	235,400	1.27	298,958
7/30/12	141,240	0.85	120,054
8/28/12	258,352	1.27	328,107
8/28/12	155,011	0.85	131,759
10/18/12	158,895	1.27	201,797
10/18/12	95,337	0.85	81,036
11/26/12	58,850	1.27	74,740
11/27/12	35,310	0.85	30,014
Outstanding at 12/31/12	9,345,253	1.14	10,613,584
2/28/13	400,000	0.85	340,000
3/1/13	(1,625,192)	0.85	(1,381,413)
3/1/13	1,625,192	0.85	1,381,413
3/13/13	800,000	1.88	1,500,000
3/13/13	480,000	0.85	408,000
6/19/13	127,200	0.85	108,120
6/19/13	212,000	1.88	397,500
7/24/13	60,000	1.88	112,500
7/24/13	100,000	1.88	187,500
7/24/13	96,000	1.25	120,000
8/29/13	80,000	1.88	150,000
8/29/13	48,000	1.25	60,000
8/29/13	(48,000)	1.25	(60,000)
10/24/13	61,764	0.85	52,499
10/24/13	10,588	0.85	9,000
10/24/13	1,552,840	0.85	1,319,914
10/24/13	(1,552,840)	0.85	(1,319,914)
10/24/13	10,000	1.25	12,500
10/24/13	38,000	1.25	47,500
11/8/13	100,000	1.88	187,500
11/8/13	60,000	1.25	75,000
12/18/13	78,000	1.25	97,500
12/18/13	78,000	1.25	97,500
12/18/13	15,000	0.85	12,750
12/18/13	1,537,840	0.85	1,307,164
Outstanding at 12/31/13	13,689,648	1.13	15,849,164

Note_11_Income_Taxes_Schedule_

Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Schedule of Deferred Tax Assets and Liabilities	'
		2013		2012
	Cumulative NOL	$	7,436,707	$	6,185,210
	Deferred Tax assets:
	Net operating loss carry forwards		2,900,316		2,412,232
	Valuation allowance		-2,900,316		-2,412,232
		$	-	$	-

Note_11_Income_Taxes_Schedule_1

Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Schedule of Effective Income Tax Rate Reconciliation	'
		2013		2012
	Income tax benefit at U. S. federal statutory rates:	$	-763,180	$	-511,264
	Stock-based compensation		273,565		9,027
	Derivative liability		1,531		3,180
	Change in valuation allowance		488,084		499,057
		$	-	$	-

Note_1_Nature_of_Operations_De

Note 1 - Nature of Operations (Details)	12 Months Ended
	Dec. 31, 2013
Details	'
Entity Incorporation, State Country Name	'Delaware
Entity Incorporation, Date of Incorporation	15-May-06

Note_2_Going_Concern_Details

Note 2 - Going Concern (Details) (USD $)	12 Months Ended							92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2013
Details	'	'	'	'	'	'	'	'
REVENUES	'	'	'	'	'	'	'	'
Net loss	1,956,872	1,310,934	2,284,393	2,119,059	730,743	1,695,766	526,833	10,668,408
Deficit accumulated during the development stage	$10,668,408	$8,711,536	'	'	'	'	'	$10,668,408

Recovered_Sheet6

Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Cash balance in excess of federally insured limit	$991,397	$0

Recovered_Sheet7

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Details) (USD $)	Dec. 31, 2012
Derivative Liability, Fair Value, Gross Asset	($5,687,262)
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	-5,687,262
Fair Value, Inputs, Level 3	'
Derivative Liability, Fair Value, Gross Asset	-5,687,262
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	($5,687,262)

Recovered_Sheet8

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Derivative liability	'	($5,687,262)
Purchases, sales, issuances and settlements (net)	$5,687,262	'

Recovered_Sheet9

Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Details) (USD $)	12 Months Ended		92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details	'	'	'
Research and development	$841,502	$939,296	$4,297,433

Recovered_Sheet10

Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,162,608	12,814,874

Recovered_Sheet11

Note 3 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended	92 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
Details	'	'
DEEMED DIVIDEND ON WARRANTS	$2,445,621	$2,445,621

Note_4_Equipment_Details

Note 4 - Equipment (Details) (USD $)	12 Months Ended		92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details	'	'	'
Depreciation expense	$144	$1,265	$5,390

Note_4_Equipment_Property_Plan1

Note 4 - Equipment: Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Property, Plant and Equipment, Gross	$5,390	$5,390
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets	-5,390	-5,246
EQUIPMENT, net	'	$144

Note_5_Accrued_Liabilities_Det

Note 5 - Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Apr. 07, 2009
Details	'	'
Probable liquidated damages	$85,738	'
Liquidated damages	'	$1,800,000	[1]
[1]	December 31, 2009, the Company's registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.

Note_6_Note_Payable_Details

Note 6 - Note Payable (Details) (USD $)	1 Months Ended				12 Months Ended		92 Months Ended
	Mar. 31, 2013		Jan. 31, 2013		Dec. 31, 2013		Dec. 31, 2013
Details	'		'		'		'
Proceeds from Unsecured Notes Payable	'		'		$55,075	[1]	'
Proceeds from related party notes payable	$5,000	[2]	$25,000	[2]	$30,000		$30,000
[1]	As of December 31, 2012, the balance on the note has been paid in full.
[2]	In April 2013, the balance on the note was repaid in full.

Note_7_Derivative_Liability_an2

Note 7 - Derivative Liability and Fair Value Measurements (Details) (USD $)	12 Months Ended					92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013
Warrants Reclassified to Derivative Liabilties	'	'	'	'	3,572,714	'
Cumulative effect of adoption of ASC 815	'	'	'	'	$1,676,633	'
Gain (loss) on derivative liability	-3,926	-8,154	'	'	'	-998,403
Warrants Issued Attached to Preferred Stock	'	1,313,533	1,704,884	676,775	953,370	'
Convertible Preferred Stock	'	1,116	1,449	575	810	'
Additional Warrants Issued as Stock Offering	'	757,223	1,022,931	391,353	286,011	'
Derivative Liability, Fair Value, Gross Liability	'	301,800	2,184,753	852,346	988,552	'
Mandatorily Redeemable Preferred Stock, Fair Value Disclosure	0	3,182,380	'	'	'	0
Warrants Fair Value	0	2,504,879	'	'	'	0
Deficit Accumulated During the Development Stage	'	'	'	'	'	'
Cumulative effect of adoption of ASC 815	'	'	'	'	$43,808	'
Minimum	'	'	'	'	'	'
Investment Warrants, Exercise Price	$0.85	'	'	'	'	'
Maximum	'	'	'	'	'	'
Investment Warrants, Exercise Price	$1.27	'	'	'	'	'

Note_7_Derivative_Liability_an3

Note 7 - Derivative Liability and Fair Value Measurements: Fair value of the preferred stock (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Derivative Liability Balance Level 3	'	$5,687,262
Derivative, Loss on Derivative	3,923	'
Stock And Warrants Removed During Period Value Preferred Stock And Warrants	($5,691,185)	'

Note_8_Capital_Stock_Preferred

Note 8 - Capital Stock: Preferred Stock (Details) (USD $)

3 Months Ended

12 Months Ended

92 Months Ended

Apr. 15, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2013

Nov. 25, 2008

Details

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Series C Issued

'

3,380

[1],[2],[3]

'

'

'

'

'

'

'

Convertible Preferred Stock Series B Issued

'

'

1,116

[1],[2],[4]

1,030

[1],[2],[4]

'

'

'

'

'

Convertible Preferred Stock Series A Issued

'

'

'

419

[1],[2],[5]

575

[1],[2],[5]

810

[1],[2],[5]

562

[1],[2],[5]

'

'

Convertible Preferred Stock issued for cash

'

'

'

'

'

'

'

'

890

[1],[2],[5]

Preferred stock issued for bridge financing

'

'

'

'

'

'

'

$889,875

'

Common Stock issued

1,082,500

[6]

'

'

'

'

'

'

'

'

Accrued dividends

'

$1,353,961

$861,872

'

'

'

'

$1,353,961

'

[1]

par value $0.10

[2]

$1,000 per share

[3]

Series C

[4]

Series B

[5]

Series A

[6]

$0.85 per common share

Note_8_Capital_Stock_Common_St

Note 8 - Capital Stock: Common Stock (Details) (USD $)

3 Months Ended

12 Months Ended

92 Months Ended

Dec. 31, 2010

Sep. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Details

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

450,000

[1]

400,000

[1]

40,000

[1]

7,500

[1]

640,000

[1]

'

'

Common stock issued for services

'

'

$34,000

$6,375

$544,000

$722,500

$1,306,875

Allocated Share-based Compensation Expense

382,500

340,000

'

16,000

289,000

'

'

Gain on shares issued for services

'

'

'

9,625

'

'

9,625

Salaries, Wages and Officers' Compensation

'

'

'

'

151,000

'

'

Extinguished accrued officer salary

'

'

'

'

$104,000

'

'

[1]

$0.85 per common share

Note_9_Warrants_Schedule_of_St1

Note 9 - Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Details	'	'	'	'	'	'
Class of Warrant or Right, Outstanding	13,689,648	9,345,253	7,274,497	4,546,682	3,478,554	2,239,173
Warrant Exercise Price	$1.13	$1.14	$1.14	$1.16	$1.17	$1.17
Warrants and Rights Outstanding	$15,849,164	$10,613,584	$8,301,757	$5,267,063	$4,074,909	$2,621,018

Note_9_Warrants_Details

Note 9 - Warrants (Details) (USD $)	12 Months Ended		92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details	'	'	'
Modification Expense	$156,477	'	'
Stock offering costs paid	550,326	221,175	1,598,278
Related party note payable	$1,353,960	$861,872	$1,353,960

Note_10_Stock_Options_Details

Note 10 - Stock Options (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jul. 12, 2010

Dec. 31, 2013

Feb. 20, 2013

Dec. 31, 2013

Feb. 20, 2013

Dec. 31, 2013

Feb. 20, 2013

Dec. 31, 2013

Feb. 20, 2013

Dec. 31, 2013

Feb. 20, 2013

Dec. 31, 2013

Feb. 20, 2013

Dec. 31, 2013

Feb. 20, 2013

Stock Options 1

Stock Options 1

Stock Options 1

Stock Options 2

Stock Options 2

Stock Options 3

Stock Options 3

Stock Options 4

Stock Options 4

Stock Options 5

Stock Options 5

Stock Options 6

Stock Options 6

Stock Options 7

Stock Options 7

Stock Options 8

Stock Options 8

Options issued to a director

'

'

'

'

100,000

'

60,000

'

60,000

'

60,000

'

60,000

'

82,400

'

117,600

'

30,000

Black-Scholes option pricing model assumptions

'

'

'

'$0.85 stock price, 10 years to maturity, 400% volatility, 2.02% risk free rate.

'

'$0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.

'

'$0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.

'

'$0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.

'

'$0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.

'

'$0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate.

'

'$0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate.

'

'$0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .88% risk free rate.

'

Amortization of ESOP Award

$667,449

$16,772

$4,952

$16,772

'

$50,928

'

$50,941

'

$50,928

'

$50,928

'

$69,918

'

$99,786

'

$25,471

'

Note_11_Income_Taxes_Details

Note 11 - Income Taxes (Details) (USD $)	12 Months Ended		92 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details	'	'	'
Provision for income taxes	'	'	'
Marginal tax rate	39.00%	'	'

Note_11_Income_Taxes_Schedule_2

Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Operating Loss Carryforwards	$7,436,707	$6,185,210
Deferred Tax Assets, Operating Loss Carryforwards	2,900,316	2,412,232
Operating Loss Carryforwards, Valuation Allowance	($2,900,316)	($2,412,232)

Note_11_Income_Taxes_Schedule_3

Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	($763,180)	($511,264)
Share-based Compensation	273,565	9,027
Derivative liability Income tax	1,531	3,180
Valuation Allowance, Deferred Tax Asset, Change in Amount	$488,084	$499,057

Note_12_Related_Party_Transact1

Note 12 - Related Party Transactions (Details) (USD $)	1 Months Ended				12 Months Ended	92 Months Ended
	Mar. 31, 2013		Jan. 31, 2013		Dec. 31, 2013	Dec. 31, 2013
Details	'		'		'	'
Proceeds from related party notes payable	$5,000	[1]	$25,000	[1]	$30,000	$30,000
Repayment of related party notes payable	'		'		$30,000	$30,000
[1]	In April 2013, the balance on the note was repaid in full.